CSL boss Perreault to leave after 10 years
Paul Perreault will leave the $143.80bn biotechnology giant in March and hand over the reins to veteran Paul McKenzie.
Csl
ASX gains 0.3pc; Star chair to exit after ASIC action
Tech, banks lead ASX higher; Star’s Heap and Lahey to leave board, contest ASIC allegations; Bendigo Bank surges on cash profit; Woodside slams gas price cap and miners drag.
The Australian’s CEO Survey 2022: CBA to HESTA
Despite rising costs, ongoing labour shortages and supply chain issues, business confidence is still growing, says Crown Resorts’ Ciaran Carruthers. CSL’s Paul Perreault disagrees.
Game changer: CSL’s $1bn bet on lifesaving hub
CSL’s major new factory will fuel a nine-fold increase in its plasma processing capacity in Australia.
CSL wins FDA approval for blockbuster drug
Chief executive Paul Perreault says the FDA’s approval for the company’s new drug Hemgenix – the world’s first gene therapy treatment for haemophilia – is ‘historic’.
Four healthcare stocks ready to rebound
Healthcare leaders struggled during the pandemic, but it’s time to look again at some of the better players.
Last Post: COP27, Bowen, nuclear and Stuff the British Gave Us
Why are climate change conferences invariably held in glamorous resorts, not in impoverished, energy-poor places where the push for renewables is meaningless?
CSL sets sights on Covid-19, influenza ‘superjab’
Combining vaccines for Covid-19 and influenza into a single shot is edging closer to reality thanks to self-amplifying messenger RNA technology, and CSL is getting in on the action.
ASX closes up; Medibank stocks among top risers
Local stocks end the day higher led by materials and energy gains. CBA hikes home loan, savings rates. Loan values fell in September. Rio lifts after winning over Turquoise investors. Inflation boost for Amcor. AGL up as Cannon-Brookes wins backing in board battle.
How CSL plans to make Vifor the jewel in its crown
Paul Perreault says Vifor Pharma, which it bought for $16.4bn this year, has huge opportunities as a global leader in the treatment of iron deficiency.
CSL opts for investment over split, buyback
CSL’s board is aware of investor interest in share buybacks and splitting but will invest in its business and pursue further acquisitions.
CSL’s plan to combat Russian energy freeze
Australia’s biggest health company, CSL, has robust strategies to protect its European plants against the threat of rolling blackouts.
Powering ahead on net zero leads only to a world of pain
As the world wakes up to the fact the climate policy goal of achieving net-zero CO2 emissions brings crippling economic pain, emerging economies are baulking at emulating the rich.
ASX drops 1.6pc; coal miners lead energy wipeout
ASX hits a three-month low as energy and miners plunge. Dollar hits 29-month low, New Hope leads coal losses, Costa smashed on CEO exit and health stock rally.
Nation’s biggest health companies vow to cut carbon footprint
Australia’s biggest health companies are launching a range of strategies to cut carbon emissions, saying environmental goals are “inextricably linked” to healthcare.
CSL blindsided by Morrison becoming health minister
The pharmaceutical company says it had no idea it had to deal with two health ministers when it was tasked with producing the majority of Australia’s Covid-19 vaccine supply.
ASX in black, Challenger, Super Retail up
ASX ends 0.3 per cent higher, recording its best close in 10 weeks. Investors pile into Challenger, BHP, Wesfarmers, Brambles and Super Retail with a flurry of earnings results. CSL lost ground after profit fell.
ASX extends gains; BHP soars, Challenger dives
ASX exits technical correction as BHP lifts on profit beat. Challenger smashed on results; Seek falls after reporting, Life360 jumps on outlook and consumer confidence rebounds.
CSL gets its mojo back
CSL’s $16.4bn acquisition of Swiss biotech Vifor Pharma gets a thumbs up from a faithful shareholder base.
ASX extends winning streak after RBA hike
ASX rises for a sixth straight day after the RBA’s 50bps hike. Zip and A2 Milk surge, Appen dives on update, Telstra completes Fetch acquisition and United Malt selloff extends.
Original URL: https://www.theaustralian.com.au/topics/csl/page/5